

CONFERENCE SCHEDULE

SUNDAY, SEPTEMBER 30, 2018

8:30 a.m.-8:45 a.m.

Welcome

Broadway Ballroom (Sixth Floor)

Jill O'Donnell-Tormey, Cancer Research Institute,
New York, NY

8:45 a.m.-11:45 a.m.

Session 1: Regulating T Cells and Their Response to Cancer

Broadway Ballroom (Sixth Floor)

Session Chair: Christoph Huber, Association for Cancer Immunotherapy (CIMT), Mainz, Germany

8:45 a.m.

T-cell exhaustion and PD-1 therapy

Rafi Ahmed, Emory University,
Atlanta, GA

9:15 a.m.

Tissue resident memory cells: At the center of tumor control

Christian Ottensmeier, University of Southampton, Southampton, United Kingdom

9:45 a.m.

Refreshment Break

Broadway Ballroom Foyer (Sixth Floor)
and Westside Ballroom (Fifth Floor)

10:15 a.m.

Genetic screens for immunotherapy target discovery

W. Nicholas Haining, Dana-Farber Cancer Institute, Boston, MA

10:45 a.m.

Dysfunction and stemness of tumor-infiltrating T cells are triggered by a common mechanism

Nicholas P. Restifo, National Cancer Institute, NIH, Bethesda, MD

CONFERENCE SCHEDULE

Session 1 (cont'd)

11:15 a.m. **PR1 Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients***

Roberta Zappasodi, Memorial Sloan Kettering Cancer Center, New York, NY

11:30 a.m. **PR2 Neoadjuvant immunotherapy precancer surgery relieves tumor-specific CD8+ T-cell dysfunction and restores memory differentiation potential***

Jake S. O'Donnell, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

11:45 a.m.-2:15 p.m.

Lunch and Poster Session A and Exhibits

Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Clinical Trials of Cancer Immunotherapies

Genetically Engineered T Cells

Maintenance of Immune Balance: Effects of Targeted and Immune Therapies

Regulating T Cells and Their Response to Cancer

Tackling the Tumor Microenvironment - Beyond T Cells

2:15 p.m.-2:45 p.m.

William B. Coley Lecture

Broadway Ballroom (Sixth Floor)

From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy

Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX

**Short talk from proffered abstract*

2:45 p.m.-6:15 p.m.

**Session 2: Tackling the Tumor
Microenvironment – Beyond T Cells**

Broadway Ballroom (Sixth Floor)

Session Cochairs: **Wolf H. Fridman**, Centre de Recherche des Cordeliers, Paris, France, and **Dmitry Gabrilovich**, The Wistar Institute, Philadelphia, PA

- 2:45 p.m. **Stromal activation in cancer immunology and immunotherapy**
Shannon J. Turley, Genentech, South San Francisco, CA
- 3:15 p.m. **Using matrix protein affinity to modulate the tumor microenvironment**
Jeffrey A. Hubbell, University of Chicago, Chicago, IL
- 3:45 p.m. **The tumor myeloid microenvironment**
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY
- 4:15 p.m. **Refreshment Break**
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)
- 4:45 p.m. **Harnessing natural and engineered properties of NKT cells for cancer immunotherapy**
Leonid S. Metelitsa, Baylor College of Medicine, Houston, TX
- 5:15 p.m. **PMN-MDSC and neutrophils: Tale of two cells in cancer**
Dmitry Gabrilovich
- 5:45 p.m. **PR3 Immune-based classification of soft-tissue sarcoma is associated with clinical outcome and unveils tertiary lymphoid structures as surrogate biomarker for the clinic***
Wei-Wu Tom Chen, National Taiwan University Hospital, Taipei, Taiwan

**Short talk from proffered abstract*

CONFERENCE SCHEDULE

Session 2 (cont'd)

6:00 p.m.

PR4 A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments*

Kevin C. Barry, University of California, San Francisco, San Francisco, CA

MONDAY, OCTOBER 1, 2018

8:15 a.m.-8:45 a.m.

Keynote Address

Broadway Ballroom (Sixth Floor)

The immunotherapy faces of Interleukin-8 and CD137

Ignacio Melero, Universidad de Navarra, University Clinic and CIMA, Pamplona, Spain

8:45 a.m.-12:45 p.m.

Session 3: Genetically Engineered T Cells

Broadway Ballroom (Sixth Floor)

Session Cochairs: Crystal L. Mackall, Stanford University

School of Medicine, Stanford, CA, and **Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY**

8:45 a.m.

CAR T-cell therapy for lymphoma and multiple myeloma

James N. Kochenderfer, National Cancer Institute, NIH, Bethesda, MD

9:15 a.m.

Engineering exhaustion-resistant CAR T cells

Crystal L. Mackall

9:45 a.m.

Cell transfer immunotherapy targeting unique somatic mutations in cancer

Steven A. Rosenberg, National Cancer Institute, NIH, Bethesda, MD

**Short talk from proffered abstract*

- 10:15 a.m. **Refreshment Break**
Broadway Ballroom Foyer (Sixth Floor)
and Westside Ballroom (Fifth Floor)
- 10:45 a.m. **Advancing CAR T cell therapy for the
treatment of brain tumors**
Christine E. Brown, City of Hope
National Medical Center, Duarte, CA
- 11:15 a.m. **Novel approaches to CAR T-cell
engineering**
Michel Sadelain, Memorial Sloan
Kettering Cancer Center, New York, NY
- 11:45 a.m. **Utilizing synthetic biology and
high-dimension probing to address
therapeutic obstacles and empower
engineered T cells with the capacity
to eradicate tumors**
Philip D. Greenberg, Fred Hutchinson
Cancer Research Center and University
of Washington School of Medicine,
Seattle, WA
- 12:15 p.m. **PR5 T cells engineered to overcome
death signaling within the tumor
microenvironment enhance adoptive
cancer immunotherapy***
Christopher A. Klebanoff, Memorial
Sloan Kettering Cancer Center,
New York, NY
- 12:30 p.m. **PR6 Dual-specific T cells and an
indirect vaccine eradicate large
solid tumors***
Clare Y. Slaney, Peter MacCallum Cancer
Centre, Melbourne, VIC, Australia

12:45 p.m.-2:15 pm.

Lunch and Exhibits

Westside Ballroom (Fifth Floor) and Broadway Ballroom
Foyer (Sixth Floor)

**Short talk from proffered abstract*

CONFERENCE SCHEDULE

2:15 p.m.-5:45 p.m.

Session 4: Maintenance of Immune Balance: Effects of Targeted and Immune Therapies

Broadway Ballroom (Sixth Floor)

Session Cochairs: Catherine Sautès-Fridman, Université Paris-Descartes, Paris, France, and **Ellen Puré**, University of Pennsylvania, Philadelphia, PA

- 2:15 p.m. **Inactivation of DNA repair to improve immune surveillance**
Alberto Bardelli, University of Turin and Candiolo Cancer Institute, Candiolo, Italy
- 2:45 p.m. **CAR T cells: On the road to a cure**
David L. Porter, University of Pennsylvania, Philadelphia, PA
- 3:15 p.m. **Targeting the immune microenvironment in breast cancer**
Peter Savas, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- 3:45 p.m. **RNA-editing derived epitopes function as cancer antigens to elicit immune responses**
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX
- 4:15 p.m. **Refreshment break**
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)
- 4:45 p.m. **Autoimmune rheumatic diseases and cancer**
Antony Rosen, Johns Hopkins University School of Medicine, Baltimore, MD
- 5:15 p.m. **PR7 Developing syngeneic NOD tumor models to profile immunotoxicity and antitumor immunity in response to cancer immunotherapies in autoimmune-prone mice***
Arabella Young, University of California San Francisco, San Francisco, CA

**Short talk from proffered abstract*

5:30 p.m.

PR8 Mechanisms of primary resistance to PD-1 checkpoint blockade*

Michelle Krogsgaard, NYU School of Medicine, New York, NY

TUESDAY, OCTOBER 2, 2018

8:15 a.m.-12:45 p.m.

Session 5: Novel Vaccine Platforms and Combinations

Broadway Ballroom (Sixth Floor)

Session Cochairs: **Nina Bhardwaj**, Icahn School of Medicine at Mount Sinai, New York, NY, and **Cornelis J.M. Melief**, Leiden University Medical Center and ISA Pharmaceuticals, Leiden, The Netherlands

8:15 a.m.

High-dimensional analysis of effective cancer immunotherapy driven by MHC-I and MHC-II neoepitopes

Matthew M. Gubin, Washington University School of Medicine, St. Louis, MO

8:45 a.m.

Personalized cancer immunotherapy (not eligible for CME credit)

Ugur Sahin, BioNTech, Mainz, Germany

9:15 a.m.

Targeting tumor neoantigen to drive effective tumor immunity

Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA

9:45 a.m.

Combination immunotherapy of cancer caused by human papilloma virus

Cornelis J.M. Melief

10:15 a.m.

Refreshment Break

Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

**Short talk from proffered abstract*

CONFERENCE SCHEDULE

Session 5 (cont'd)

- 10:45 a.m. **Oncolytic viruses: Potential for in situ antitumor vaccination and combination with checkpoint blockade**
Alan Melcher, The Institute of Cancer Research, London, United Kingdom
- 11:15 a.m. **Nanodisc platform technology for cancer vaccination**
James J. Moon, University of Michigan, Ann Arbor, MI
- 11:45 a.m. **Peptide-TLR-7/8 agonist conjugate vaccines chemically programmed for nanoparticle self-assembly to enhance the magnitude and breadth of anticancer neoantigen CD8 T cell immunity**
Robert Seder, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
- 12:15 p.m. **PR9 Intratumoral delivery of engineered modified vaccinia virus Ankara expressing Flt3L and OX40L for in situ therapeutic cancer vaccination***
Liang Deng, Memorial Sloan Kettering Cancer Center, New York, NY
- 12:30 p.m. **PR10 Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy***
Elizabeth C. Evans, Vaccinex, Inc., Rochester, NY

12:45 p.m.-3:15 p.m.

Lunch and Poster Session B and Exhibits

Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Convergence of Technology and Cancer Immunotherapy

Microbiome and Metabolism

**Short talk from proffered abstract*

Mutational Analysis and Predicting Response to Immunotherapy

Novel Vaccine Platforms and Combinations

Trials in Progress

Other

3:15 p.m.-6:45 p.m.

Session 6: Mutational Analysis and Predicting Response to Immunotherapy

Broadway Ballroom (Sixth Floor)

Session Cochairs: **Drew M. Pardoll**, Johns Hopkins University School of Medicine, Baltimore, MD, and **Ton N. Schumacher**, Netherlands Cancer Institute, Amsterdam, The Netherlands

- | | |
|-----------|---|
| 3:15 p.m. | T-cell recognition in human cancer
Ton N. Schumacher |
| 3:45 p.m. | Measuring the emergence of non-self in tumors
Benjamin D. Greenbaum, Icahn School of Medicine at Mount Sinai, New York, NY |
| 4:15 p.m. | Application of TMB in the clinic to predict response to immunotherapy
Naiyer Rizvi, Columbia University Medical Center, New York, NY |
| 4:45 p.m. | Refreshment break
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor) |
| 5:15 p.m. | Cancer genetics and response to immunotherapy
Drew M. Pardoll |
| 5:45 p.m. | Mapping immune recognition of non-self neoantigens in human pancreatic cancer
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY |

CONFERENCE SCHEDULE

Session 6 (cont'd)

- 6:15 p.m. **PR11 CX3CR1+CD8+ T cells are responsible to the clinical benefit of chemoimmunotherapy in metastatic melanoma patients after disease progression on PD-1 blockade***
Yiyi Yan, Mayo Clinic College of Medicine, Rochester, MN
- 6:30 p.m. **PR12 Functional identification and therapeutic targeting of tumor neoantigens***
Stephen Philip Schoenberger, La Jolla Institute for Allergy and Immunology, La Jolla, CA

WEDNESDAY, OCTOBER 3, 2018

8:15 a.m.-10:45 a.m.

Session 7: Convergence of Technology and Cancer Immunotherapy

Broadway Ballroom (Sixth Floor)

Session Cochairs: Carl G. Figdor, Radboud University Nijmegen, Nijmegen, The Netherlands, and **Özlem Türeci**, Ganymed Pharmaceuticals, Mainz, Germany

- 8:15 a.m. **Determinants of effective tumor immunity**
Nir Hacohen, Massachusetts General Hospital and Broad Institute, Cambridge, MA
- 8:45 a.m. **Microengineered physiologic biomimicry: Human organs-on-chips**
Dan Dongeun Huh, University of Pennsylvania, Philadelphia, PA

**Short talk from proffered abstract*

- 9:15 a.m. **Enhancing the function of CAR T cells via a universal vaccine strategy**
Darrell Irvine, MIT/Koch Institute for Integrative Cancer Research, Cambridge, MA
- 9:45 a.m. **PR13 A new high-performance HLA ligand identification strategy enables prediction of T-cell tolerance to neoepitopes***
Martin G. Klatt, Memorial Sloan Kettering Cancer Center, New York, NY
- 10:00 a.m. **PR14 Identification of specificity TCR groups of tumor antigen-specific T cells***
Liang Chen, Stanford University, Stanford, CA
- 10:15 a.m. **Refreshment break**
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

10:45 a.m.-12:45 p.m.

Session 8: Microbiome and Metabolism

Broadway Ballroom (Sixth Floor)

Session Cochairs: Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France, and **Laurence Zitvogel**, Institut Gustave Roussy, Paris, France

- 10:45 a.m. **Manipulating the gut microbiome to improve immunotherapy of melanoma**
Hassane M. Zarour, University of Pittsburgh School of Medicine, Pittsburgh, PA
- 11:15 a.m. **Targeting the gut and tumor microbiome in response and toxicity to cancer therapy**
Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

**Short talk from proffered abstract*

CONFERENCE SCHEDULE

Session 8 (cont'd)

11:45 a.m. **Control of tissue immunity and repair by the microbiome**

Yasmine Belkaid, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

12:15 p.m. **PR15 The oncometabolite R-2-hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via Aryl Hydrocarbon Receptor signaling***

Mirco Friedrich, German Cancer Research Center (NI), Heidelberg, Germany

12:30 p.m. **PR16 Mucosal-associated invariant T cells respond to the cutaneous microbiota and promote skin immunity***

Michael G. Constantinides, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

12:45 p.m.-1:00 p.m.
Closing Remarks

Broadway Ballroom (Sixth Floor)

Margaret Foti, American Association for Cancer Research, Philadelphia, PA

1:00 p.m.
Meeting Ends

**Short talk from proffered abstract*